BR9407092A - Processo para a expressao em alto nível da proteína porina meningocócica do grupo B ou sua proteína de fusao na membrana externa em E coli processo para a purificaçao da proteína porina meningocócica do grupo B ou sua proteína de fusao na membrana externa processo para redobrar a proteína porina meningocócica do grupo B ou sua proteína de fusao na membrana externa proteína porina meningocócica do grupo B ou sua proteína de fusao na membrana externa substancialmente puras vacina contendo a - Google Patents

Processo para a expressao em alto nível da proteína porina meningocócica do grupo B ou sua proteína de fusao na membrana externa em E coli processo para a purificaçao da proteína porina meningocócica do grupo B ou sua proteína de fusao na membrana externa processo para redobrar a proteína porina meningocócica do grupo B ou sua proteína de fusao na membrana externa proteína porina meningocócica do grupo B ou sua proteína de fusao na membrana externa substancialmente puras vacina contendo a

Info

Publication number
BR9407092A
BR9407092A BR9407092A BR9407092A BR9407092A BR 9407092 A BR9407092 A BR 9407092A BR 9407092 A BR9407092 A BR 9407092A BR 9407092 A BR9407092 A BR 9407092A BR 9407092 A BR9407092 A BR 9407092A
Authority
BR
Brazil
Prior art keywords
meningococcal
group
protein
fusion protein
porin
Prior art date
Application number
BR9407092A
Other languages
English (en)
Inventor
Milan S Blake
Joseph Y Tai
Huilin L Qi
Shu-Mei Liang
Lucjan J J Hronowski
Jeffrey K Pullen
Original Assignee
Univ Rockefeller
North American Vaccine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rockefeller, North American Vaccine Inc filed Critical Univ Rockefeller
Publication of BR9407092A publication Critical patent/BR9407092A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/848—Escherichia
    • Y10S435/849—Escherichia coli

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
BR9407092A 1993-07-23 1994-07-22 Processo para a expressao em alto nível da proteína porina meningocócica do grupo B ou sua proteína de fusao na membrana externa em E coli processo para a purificaçao da proteína porina meningocócica do grupo B ou sua proteína de fusao na membrana externa processo para redobrar a proteína porina meningocócica do grupo B ou sua proteína de fusao na membrana externa proteína porina meningocócica do grupo B ou sua proteína de fusao na membrana externa substancialmente puras vacina contendo a BR9407092A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/096,182 US5439808A (en) 1993-07-23 1993-07-23 Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
PCT/US1994/008327 WO1995003413A1 (en) 1993-07-23 1994-07-22 High level expression, purification and refolding of the neisseria meningitidis outer membrane group b porin proteins

Publications (1)

Publication Number Publication Date
BR9407092A true BR9407092A (pt) 1996-09-03

Family

ID=22256136

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9407092A BR9407092A (pt) 1993-07-23 1994-07-22 Processo para a expressao em alto nível da proteína porina meningocócica do grupo B ou sua proteína de fusao na membrana externa em E coli processo para a purificaçao da proteína porina meningocócica do grupo B ou sua proteína de fusao na membrana externa processo para redobrar a proteína porina meningocócica do grupo B ou sua proteína de fusao na membrana externa proteína porina meningocócica do grupo B ou sua proteína de fusao na membrana externa substancialmente puras vacina contendo a

Country Status (12)

Country Link
US (3) US5439808A (pt)
EP (1) EP0713530A4 (pt)
JP (1) JPH09500538A (pt)
AU (1) AU690570B2 (pt)
BR (1) BR9407092A (pt)
CA (1) CA2167677A1 (pt)
FI (1) FI960309A (pt)
NO (1) NO960256L (pt)
NZ (1) NZ269996A (pt)
PL (1) PL182573B1 (pt)
RU (1) RU2181378C2 (pt)
WO (1) WO1995003413A1 (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153406A (en) * 1993-07-23 2000-11-28 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane protein P2 from Haemophilus influenzae type B
CA2182976C (en) * 1994-02-09 2011-07-12 Daryll A. Emery Active immunization using a siderophore receptor protein
US5830479A (en) * 1994-02-09 1998-11-03 Willmar Poultry Company, Inc. Active immunization using a siderophore receptor protein
WO1996030043A1 (en) * 1995-03-24 1996-10-03 Ophidian Pharmaceuticals Treatment for verotoxin-producing escherichia coli
US6284884B1 (en) 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
KR19990082265A (ko) * 1996-02-01 1999-11-25 다니엘 제이. 압둔-나비 효모중에서 b군 나이세리아 멘인기티디스 외막(mb３)단백질을 발현시키는 방법 및 백신
GB9614700D0 (en) 1996-07-12 1996-09-04 Medical Res Council Over-expression of proteins in E.Coli
US6030810A (en) 1997-02-26 2000-02-29 Delgado; Stephen Gregory Cloned tetrodotoxin-sensitive sodium channel α-subunit and a splice variant thereof
AU748973B2 (en) 1997-07-17 2002-06-13 Baxter Healthcare Sa Immunogenic conjugates comprising a group B meningococcal porin and an H. influenzae polysaccharide
SE9704175D0 (sv) * 1997-11-14 1997-11-14 Alfa Laval Agri Ab An animal stall
US7335477B2 (en) * 1997-12-24 2008-02-26 The United States Of America As Represented By The Secretary Of The Navy Truncated recombinant major outer membrane protein antigen (r56) of Orientia tsutsugamushi strains Karp, Kato and Gilliam and its use in antibody based detection assays and vaccines
US7638130B2 (en) * 1997-12-24 2009-12-29 The United States Of America As Represented By The Secretary Of The Navy Truncated recombinant major outer membrane protein antigen (R56) of Orientia tsutsugamushi strains Karp, Kato and Gilliam and its use in antibody based detection assays and vaccines
US6482415B1 (en) * 1997-12-24 2002-11-19 The United States Of America As Represented By The Secretary Of The Navy Expression and refolding of truncated recombinant major outer membrane protein antigen (r56) of Orientia tsutsugamushi and its use in antibody based detection assays and vaccines
DE69941567D1 (de) 1998-01-14 2009-12-03 Novartis Vaccines & Diagnostic Antigene aus neisseria meningitidis
US6284250B1 (en) * 1998-02-05 2001-09-04 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Simplified method for removing free protein during preparation of protein-polysaccharide conjugates and vaccines using restricted-access media
CN101293920B (zh) 1998-05-01 2012-07-18 诺华疫苗和诊断公司 脑膜炎奈瑟球菌抗原和组合物
NZ509986A (en) * 1998-08-19 2003-10-31 Baxter Healthcare S Immunogenic beta-propionamido-linked polysaccharide and oligosaccharide protein conjugates as vaccines
US20110045011A1 (en) * 1998-12-22 2011-02-24 Wei-Mei Ching TRUNCATED RECOMBINANT MAJOR OUTER MEMBRANE PROTEIN ANTIGEN (R56) OF ORIENTIA TSUTSUGAMUSHI STRAINS KARP, KATO and GILLIAM AND ITS USE IN ANTIBODY BASED DETECTION ASSAYS AND VACCINES
US7081244B2 (en) * 1999-02-22 2006-07-25 Health Protection Agency Neisserial vaccine compositions and methods
DK1154791T3 (da) 1999-02-22 2008-06-16 Health Prot Agency Neisseria-vaccinesammensætninger og fremgangsmåder
NZ530640A (en) 1999-04-30 2006-06-30 Chiron S Conserved neisserial antigens
CA2929348A1 (en) * 1999-05-19 2000-11-30 Novartis Vaccines And Diagnostics S.R.L. Combination neisserial compositions
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
AU1875301A (en) 1999-11-29 2001-06-04 Chiron S.P.A. 85kda neisserial antigen
RU2279889C2 (ru) 2000-01-17 2006-07-20 Чирон С.Р.Л. ВАКЦИНА ВЕЗИКУЛ НАРУЖНЫХ МЕМБРАН (OMV), СОДЕРЖАЩАЯ БЕЛКИ НАРУЖНОЙ МЕБРАНЫ N.Meningitidis СЕРОЛОГИЧЕСКОЙ ГРУППЫ В
ES2391153T3 (es) 2000-02-28 2012-11-22 Novartis Vaccines And Diagnostics S.R.L. Expresión heteróloga de proteínas de Neisseria
ATE322288T1 (de) * 2001-01-03 2006-04-15 Epitopix Llc Zusammensetzungen zur immunisierung sowie deren verwendung
WO2002083069A2 (en) * 2001-04-13 2002-10-24 United States Of America As Represented By The Secretary Of The Navy Recombinant proteins of orientia tsutsugamushi
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
WO2004011027A1 (en) * 2002-07-30 2004-02-05 Baxter International Inc. Chimeric multivalent polysaccharide conjugate vaccines
EP1961427A3 (en) * 2002-08-02 2009-11-04 GlaxoSmithKline Biologicals S.A. Neisserial vaccine compositions comprising a combination of antigens
US20040197845A1 (en) * 2002-08-30 2004-10-07 Arjang Hassibi Methods and apparatus for pathogen detection, identification and/or quantification
DE60335477D1 (de) 2002-10-11 2011-02-03 Novartis Vaccines & Diagnostic Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien
BRPI0411815A (pt) 2003-06-23 2006-08-08 Baxter Int vacinas contra neisseria meningitidis do tipo y e suas combinações meningocócicas
WO2005028665A2 (en) * 2003-09-19 2005-03-31 Epitopix, Llc Campylobacter polypeptides and methods of use
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
JP4993750B2 (ja) 2005-01-27 2012-08-08 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド 髄膜炎菌に起因する疾患に対する広域防御のための、ｇｎａ１８７０を基にした小胞ワクチン
PT2401377T (pt) 2009-02-27 2016-08-18 Novartis Ag Sistema de vectores de expressão compreendendo dois marcadores de selecção
AU2011300418B2 (en) 2010-09-10 2016-05-12 Glaxosmithkline Biologicals Sa Meningococcus overexpressing NadA and/or NHBA and outer membrane vesicles derived therefrom
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
US10376573B2 (en) 2012-06-14 2019-08-13 Glaxosmithkline Biologicals Sa Vaccines for serogroup X meningococcus
BR112016001182A2 (pt) 2013-07-31 2017-08-29 Novartis Ag Vetores de seleção e métodos de seleção de células hospedeiras eucarióticas
WO2015033251A2 (en) 2013-09-08 2015-03-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10166280B2 (en) 2016-06-08 2019-01-01 Epitopix, Llc Polypeptides and immunizing compositions containing Bacillus polypeptides and methods of use
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4134214A (en) * 1977-08-05 1979-01-16 Merck & Co., Inc. Freeze-drying process for the preparation of meningococcus vaccine without degradation of potency
US4271147A (en) * 1980-01-10 1981-06-02 Behringwerke Aktiengesellschaft Process for the isolation of membrane proteins from Neisseria meningitidis and vaccines containing same
EP0049296B1 (en) * 1980-10-02 1985-03-27 Schering Corporation Injectable rabies vaccine composition and method for preparing same
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4451446A (en) * 1982-03-04 1984-05-29 Smithkline-Rit Process for the preparation of polysaccharide-protein complexes from bacterial capsules, obtained products and immunogenic compositions containing them
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
US5192540A (en) * 1988-04-19 1993-03-09 American Cyanamid Company Haemophilus influenzae type b oxidized polysaccharide-outer membrane protein conjugate vaccine
ATE105189T1 (de) * 1988-04-19 1994-05-15 American Cyanamid Co Haemophilus influenzae typ b polysaccharidaussermembranprotein-konjugat als impfstoff.
EP0351604B1 (en) * 1988-06-29 1994-09-14 The Rockefeller University Neisserial vaccines
AU640118B2 (en) * 1988-12-19 1993-08-19 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur Meningococcal class 1 outer-membrane protein vaccine
WO1990011777A1 (en) * 1989-03-31 1990-10-18 Immunomed Corporation Preparation of unassembled pilus subunits and vaccines containing them
IL95578A (en) * 1989-09-15 1998-08-16 Gen Hospital Corp A vaccine made from polysaccharide and protein
KR0158436B1 (ko) * 1989-12-14 1998-12-01 피에르 오. 페론 개선된 수막염균성 폴리사카라이드 결합체 백신
FI903414A (fi) * 1990-07-06 1992-01-07 Kansanterveyslaitos Produktion av proteiner i grampositiva bakterier.
CU22302A1 (es) * 1990-09-07 1995-01-31 Cigb Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales
ES2202297T3 (es) * 1990-07-16 2004-04-01 University Of North Carolina At Chapel Hill Proteinas antigenicas de n. meningitidis reprimibles con hierro relacionadas con la familia de toxinas hemolisina.
CA2047031A1 (en) * 1990-07-19 1992-01-20 Stephen Marburg Peptide-polysaccharide-protein conjugate vaccines
EP0467714A1 (en) * 1990-07-19 1992-01-22 Merck & Co. Inc. The class II protein of the outer membrane of neisseria meningitidis
ATE253114T1 (de) * 1990-08-23 2003-11-15 Univ North Carolina Transferrin bindende proteine aus neisseria- gonorrhoeae und neisseria-meningitidis
CA2057536C (en) 1990-12-21 1999-10-26 John J. Dunn Cloning and expression of borrelia lipoproteins
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
WO1992016230A1 (en) * 1991-03-15 1992-10-01 Univax Biologics Incorporated Lipid a analog/immunogenic carrier conjugates, the use thereof as vaccines and polyvalent hyperimmune gammaglobulins
CA2071088A1 (en) * 1991-06-19 1992-12-20 Emilio A. Emini Conjugates of the class ii protein of the outer membrane of neisseria meningitidis and of hiv-1 related peptides, and vaccines containing same
US5425946A (en) * 1992-08-31 1995-06-20 North American Vaccine, Inc. Vaccines against group C Neisseria meningitidis

Also Published As

Publication number Publication date
EP0713530A4 (en) 2002-09-18
JPH09500538A (ja) 1997-01-21
US5439808A (en) 1995-08-08
PL182573B1 (pl) 2002-01-31
US5879686A (en) 1999-03-09
PL312712A1 (en) 1996-05-13
US6013267A (en) 2000-01-11
CA2167677A1 (en) 1995-02-02
NZ269996A (en) 1997-10-24
RU2181378C2 (ru) 2002-04-20
AU690570B2 (en) 1998-04-30
AU7371694A (en) 1995-02-20
EP0713530A1 (en) 1996-05-29
FI960309A (fi) 1996-03-22
WO1995003413A1 (en) 1995-02-02
NO960256L (no) 1996-03-20
FI960309A0 (fi) 1996-01-23
NO960256D0 (no) 1996-01-22

Similar Documents

Publication Publication Date Title
BR9407092A (pt) Processo para a expressao em alto nível da proteína porina meningocócica do grupo B ou sua proteína de fusao na membrana externa em E coli processo para a purificaçao da proteína porina meningocócica do grupo B ou sua proteína de fusao na membrana externa processo para redobrar a proteína porina meningocócica do grupo B ou sua proteína de fusao na membrana externa proteína porina meningocócica do grupo B ou sua proteína de fusao na membrana externa substancialmente puras vacina contendo a
BR9105318A (pt) Processo e sistema de membrana aperfeicoados
BR9204274A (pt) Processo e sistema para a producao de oxigenio em membrana
FI954636A0 (fi) Annostelujärjestelmä säilöntäaineilta vapaiden steriililiuosten annostelemiseksi
BR9405708A (pt) Sistema de processo de rotulagem
DE69421889D1 (de) Modifizierte Glasfasermembranen für Festphase-Extraktionsreinigung von DNA
BR9305060A (pt) Sistema de membrana permeável multi-estágio e processo de separação de fluido de membrana permeável multi-estágio
BR8904560A (pt) Membrana de afinidade polimerica,processo para preparacao de membranas de afinidade e processo para seletivamente remover materiais biologicos de fluidos
DE69421432D1 (de) Optische Kollimatoren-Matrix und Verfahren zur Ausrichtung ihrer Achsen
BR9305141A (pt) Processo e sistema de membrana aperfeiçoados para a produção, em alta ou muito alta pureza, do componente menos seletivamente permeável de um gás de alimentação contendo o citado componente e um componente mais seletivamente permeável
BR9000731A (pt) Processo para separacao de sais em agua do mar
NO965319L (no) Rutil titandioksyd, og fremgangsmåte for fremstilling derav
BR9103131A (pt) Sistema e processo aperfeicoados de controle com membrana/desoxo
PT656014E (pt) Proteina rib, uma proteina da superficie celular que confere imunidade a muitas estirpes de estreptococos do grupo b: processo para purificacao da proteina, estojo de reagentes e composicao farmaceutica
PT84041B (pt) Processo para a preparacao do cloridrato de s-(-)-1-propil-2',6'-pipecoloxilidido monohidratado opticamente puro e de composicoes farmaceuticas que o contem
BR9407144A (pt) Processo para a expressão de alto nível da proteina de membrana externa P2 de haemophilus influenzae tipo B (HIB-P2) em E.coli; processo de purifição da proteina de membrana externa P2 ou proteina de fusão da mesma;processo de reduplicação da proteina de membrana externa P2 ou proteina de fusão obtida; proteina de membrana externa P2 reduplicada, substancialmente pura, a partir de haemophilus influenzae tipo B (HIB-P2) ou proteina de fusão da mesma; vacina compreendendo a proteina de membrana externa P2 de hamophilus influenzae tipo B (HIB-P2) ou uma proteina de fusão da mesma; processo para obter uma proteina P2 ou conjugado proteina de fusão P2-polissacarídeo; processo para evitar a meningite bacteriana em um animal; vetor pNV-3; vetor pNV-2, e vetor pNV-6
DE69403954D1 (de) Verschlusskappen für kulturflaschen
BR9104205A (pt) Acidos piridin-2-carboxilicos,com substituicao na posicao 4 ou 5,processo para sua preparacao,medicamentos e processo para sua preparacao
BR9600370A (pt) Benzenossulfoniluréias e-tiouréias substituídas processo para a sua preparação seus usos e medicamento contendo as mesmas
IT216531Z2 (it) Chiusura di sicurezza in particolare per flaconi di medicinali o simili.
NO930775L (no) Bergingssystem for ubemannede fartöyer
BR9405229A (pt) Processo para a preparação de dióxido de titânio
BR9600290A (pt) Tiofenossulfoniluréia ou-tioréia substituída processo para sua preparação seus usos e medicamento contendo-as
DE59301797D1 (de) Verschluss für eine Medikamentenflasche
NO932097D0 (no) Myke farmasoeytiske kapsler som inneholder lysinclonixinatog fremgangsmaate for deres fremstilling

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
B09B Patent application refused [chapter 9.2 patent gazette]